Roche: experimental lung cancer drug shrinks tumours
(CercleFinance.com) - Three clinical trials have showed that Roche's experimental drug entrectinib shrank tumours in over three-quarters of people with non-small cell lung cancer, the Swiss drugmaker said late on Monday.
In a pivotal phase II trial and two phase I studies, the drug that inhibits the activity of proteins behind the proliferation of certain cancers, shrank tumours in 77.4% of people with locally advanced or metastatic ROS1-positive NSCLC, Roche said.
In addition, entrectinib demonstrated a durable response of more than two years, the company said.
Importantly, entrectinib was shown to shrink tumours in over half of people with cancer in the central nervous system, it added.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In a pivotal phase II trial and two phase I studies, the drug that inhibits the activity of proteins behind the proliferation of certain cancers, shrank tumours in 77.4% of people with locally advanced or metastatic ROS1-positive NSCLC, Roche said.
In addition, entrectinib demonstrated a durable response of more than two years, the company said.
Importantly, entrectinib was shown to shrink tumours in over half of people with cancer in the central nervous system, it added.
Copyright (c) 2018 CercleFinance.com. All rights reserved.